Trade secrets are independent of patent and/or H-W.
If clinical data is considered a protected trade secret, why does Hatch-Waxman have a statutory provision that grants data exclusivity for new molecular entities and new indications? And why does the newly enacted FoB law have a provision that grants data exclusivity?
Market Data 
Markets 
AI
